Mr. Carpenter is a leader and pioneer in the healthcare and biotechnology industries. He is currently a director of Genzyme Corporation and president of Boston Medical Investors, Inc. Bob was a founder and chairman of GelTex Pharmaceuticals, which merged with Genzyme in 2000, and a founder, president and CEO of VacTex, which was acquired by Aquila Biopharmaceuticals in 1998. He was also chairman of the board, president and CEO of Integrated Genetics, Inc., a biotechnology company that merged with Genzyme Corporation in 1989. Following that merger and until 1991, Bob was EVP, CEO and chairman of its subsidiary IG Laboratories, Inc. Bob is a graduate of West Point. He earned his master's in computer science from Stanford and his MBA from Harvard Business School.
Mr. Herndon comes to Hydra with over 25 years of experience in the healthcare and biotechnology industries, with a proven track record in building successful business infrastructures, pioneering innovative corporate and regulatory processes and advancing products through development. His industry experience includes senior management positions at Genzyme Corporation and Antigenics Inc., where he led some of the companies' most strategic and important initiatives. At Antigenics, Russ served as Chief Operating Officer and President from November 2000 through December 2005. He was with Genzyme Corporation from 1989 through 2000 holding various management positions, including President of Genzyme Tissue Repair, Senior Vice President of Genzyme Tissue Repair and Vice President of regulatory affairs for Genzyme Corporation. Prior to joining Genzyme, Russ gained extensive experience in the area of quality systems, including management positions at Patton Company, Paco Research & Development and Alcon Laboratories Incorporated. Russ received a bachelor's degree in biology from Barton College and is a graduate of the Management Development Program at Harvard Business School.
Ms. George brings more than 20 years of biopharmaceutical industry experience to ATV, including 10 years at Genzyme Corporation. At Genzyme, she held a variety of operational roles in marketing, product development and business development, including Vice President of Global Sales and Marketing. She also worked as Vice President and Founder of Genzyme's Tissue Repair Division, where she was responsible for identifying new product opportunities and potential acquisition candidates. In 1998 Jean joined the venture capital community when she was appointed to lead BancBoston Ventures' life sciences investments. At BancBoston Ventures Jean led investments in Neurometrix (NASDAQ: NURU), Microbia, NuGenesis Technologies (acquired by Waters), and Syntonix Pharmaceuticals Biogen-Idec. In addition to her extensive operating and investment background, Jean also spent six years working in chemistry and bioresearch. Jean holds an M.B.A. from Simmons College Graduate School of Management and a B.S. from the University of Maine.
Paul Goldenheim, M.D.
Dr. Goldenheim is trained as a pulmonary physician and is currently working as a director and consultant in the field of biotechnology, serving on the boards of directors of several companies (including BIND, Promedior, and Hydra Biosciences). He has a long history in pharmaceutical research, development, and management, most recently as President of TransForm Pharmaceuticals (acquired by Johnson & Johnson) and Vice-Chairman of the Board of Directors of Hypnion (acquired by Eli Lilly). Dr. Goldenheim has authored numerous scientific publications and been an inventor on a number of pharmaceutical patents. Dr. Goldenheim also serves on the board of directors of The Big Apple Circus. He received his A.B. from Harvard College magna cum laude with highest honors in biochemical sciences and his M.D. from Harvard Medical School.
Steven E. Hall, Ph.D.
Dr. Hall brings more than 25 years of pharmaceutical experience from both multinational pharmaceutical companies and biotech organizations to Lilly Ventures. Prior to joining Lilly Ventures, Dr. Hall was Sr. V.P., R&D at Serenex, Inc. where he was also a co-founder. There he recruited and led a team in developing a novel discovery technology and applied it to a project that advanced from a novel screen to first patient dosed in just over three years. This novel orally-active Hsp90 inhibitor was the subject of strong interest across the industry and led to the acquisition of Serenex by Pfizer in April 2008. Prior to joining Serenex, Dr. Hall was Site Director, Sphinx Labs, Eli Lilly where he oversaw lead generation efforts in the areas of combinatorial chemistry, automation, high-throughput screening, biomolecular research, and information technology. There he was a key member of a small team that developed and executed a strategy to partner Lilly’s expertise in high-throughput chemistry with three Japanese pharmaceutical companies with an aggregate value of more than $75MM. Dr. Hall is the author of more than 40 papers and 60 patents. Dr. Hall received his BS in chemistry from Central Michigan University and his Ph.D. in organic chemistry from Massachusetts Institute of Technology.
Vincent Miles, Ph.D.
Dr. Miles is an Executive Partner at Abingworth with over 30 years experience in the biotechnology industry. Before joining Abingworth in 2007 he was Senior VP of Business Development at Alnylam Pharmaceuticals, an Abingworth portfolio company. Previously, Vincent was at Millennium Pharmaceuticals where he held VP positions in business development, strategic planning and corporate communications. Formerly he was Director of the technology transfer office at the Dana-Farber Cancer Institute and held VP positions in business development and R&D at RiboGene and Pharmacia, having begun his career at Amersham International in R&D. Vincent is on the boards of Hydra Biosciences and PrimeraDx. He has a BSc in biochemistry and a PhD in molecular biology from University College London.